Memphasys CapEx/D&A

What does Memphasys do? Memphasys Ltd. develops medical devices, diagnostics, and media for assisted reproduction technology (ART) in humans and animals. The company's product pipeline includes Felix, a patented automated device for separating high-quality sperm from semen in human IVF procedures, ROSA, an in vitro diagnostic for assessing oxidative stress in semen and blood samples, and AI-Port, a system for storing and transporting animal semen without freezing for up to four days. Felix targets the global IVF market, ROSA serves clinics and research facilities analyzing reproductive health, and AI-Port is designed for livestock artificial insemination providers. The company monetizes through direct sales of these proprietary products to healthcare providers, fertility clinics, and agricultural biotechnology firms. Felix, with its patented technology for DNA-safe sperm separation, addresses a significant market need in human fertility treatments. ROSA provides diagnostic capabilities for clinics evaluating oxidative stress in reproductive samples, while AI-Port offers a competitive advantage in livestock breeding by eliminating the need for frozen semen transport. These products are sold directly to specialized buyers within their respective sectors without intermediaries. The company generates revenue primarily from the sale of its three core products: Felix for human IVF, ROSA for diagnostic assessments, and AI-Port for animal semen storage and transport. These products target distinct segments—human fertility clinics, reproductive health research institutions, and livestock artificial insemination businesses—each with clear purchasing patterns and demand drivers. Memphasys focuses on selling directly to these end-users rather than through third-party distributors. Memphasys is one of the most popular companies on Eulerpool.